通过基于结构的虚拟查,初步结构-活性关系研究和生物评估,发现了新型和选择性的Farnesoid X受体对抗剂
Xiaodong Dou1, Tongyu Huo1, Yameng Liu2
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
European journal of medicinal chemistry
|March 28, 2024
概括
研究人员确定了新的p-乙胺二硫酸衍生物作为Farnesoid X受体 (FXR) 抗剂. 化合物F44-A13在细胞和动物模型中有效降低胆固醇和LDL-C水平,显示出对代谢疾病治疗的希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 法内索伊德X受体 (FXR) 调节胆酸,脂质和葡萄糖的新陈代谢.
- 通过降低胆固醇和LDL-C,FXR抑制显示出治疗代谢综合征和脂质疾病的潜力.
- 新的FXR对抗剂是治疗开发所需的.
研究的目的:
- 为了识别和描述新的FXR对手.
- 为了评估一种新型的p-乙胺二硫酸盐衍生物支架的有效性.
- 在临床前模型中评估化合物F44-A13的治疗潜力.
主要方法:
- 多阶段查以确定FXR对手.
- 在体外细胞测试以评估FXR抑制和选择性.
- 在C57BL/6小鼠体内药理学研究.
主要成果:
- 化合物F44-A13是一种p-乙胺二硫酸盐衍生物,被确定为一种强大的FXR抗体 (IC50 = 1.1μM).
- 在其他11个核受体上,F44-A13对FXR具有很高的选择性.
- 在体外和体内研究表明,F44-A13有效降低胆固醇,甘油三和LDL-C水平,并抑制了FXR基因.
结论:
- F44-A13是一种高度选择性的FXR抗体,具有显著的降脂效应.
- 这种化合物代表了进一步FXR研究的有希望的分子.
- F44-A13可以作为开发新型治疗方法的基础,用于与脂质疾病相关的代谢疾病.
更多相关视频
相关概念视频
Structure-Activity Relationships and Drug Design
716
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
716
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Drug-Receptor Interactions
5.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.2K


